Henning Jann
YOU?
Author Swipe
View article: Prognostic Factors in Neuroendocrine Neoplasms of the Rectum
Prognostic Factors in Neuroendocrine Neoplasms of the Rectum Open
Background/Objectives: Neuroendocrine neoplasms (NENs) of the rectum (rNEN) are a rare and heterogeneous group of tumors that can vary greatly in their biological behavior, from benign to highly aggressive. While small and well-differentia…
View article: Automatic 3D Tracking of Liver Metastases: Follow-Up Assessment of Cancer Patients in Contrast-Enhanced MRI
Automatic 3D Tracking of Liver Metastases: Follow-Up Assessment of Cancer Patients in Contrast-Enhanced MRI Open
Background: Tracking differential growth of secondary liver metastases is important for early detection of progression but remains challenging due to variable tumor growth rates. We aimed to automate accurate, consistent, and efficient lon…
View article: Data from Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study
Data from Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study Open
Purpose:Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are relatively indolent but can be more aggressive. The current recommendations for using serum chromogranin A (CgA) for patients with GEP-NET are equivocal. This study was des…
View article: Figure 1 from Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study
Figure 1 from Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study Open
A, Clinical trial profile. Inclusion and exclusion criteria. B, Study site visit information for intention-to-diagnose population. ECOG, Eastern Cooperative Oncology Group.
View article: Table 1 from Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study
Table 1 from Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study Open
Patient characteristics at baseline.
View article: Figure 3 from Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study
Figure 3 from Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study Open
Kaplan–Meier plots with proportion of progression-free patients with GEP-NET (%) during 24 months of follow-up in the intention-to-diagnose population, with stratification by primary tumor site (A; largest subgroups—pancreas and sma…
View article: Supplementary Data 1 from Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study
Supplementary Data 1 from Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study Open
Supplementary data for CASPAR pilot study, tables and figures
View article: Figure 2 from Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study
Figure 2 from Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study Open
A, ROC curves for diagnosis of tumor progression in the intention-to-diagnose population with corresponding AUC. B, Box plots of continuous ΔCgA, simple ΔCgA, and CgA concentrations are shown with log-scaled axes. Strata of f…
View article: Table 2 from Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study
Table 2 from Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study Open
Contingency table and diagnostic performance metrics of intention-to-diagnose population.
View article: Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study
Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study Open
Purpose: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are relatively indolent but can be more aggressive. The current recommendations for using serum chromogranin A (CgA) for patients with GEP-NET are equivocal. This study was de…
View article: Emergency surgery influences oncological outcome in small intestinal neuroendocrine tumors
Emergency surgery influences oncological outcome in small intestinal neuroendocrine tumors Open
Background and aims: Patients with small intestinal neuroendocrine tumors (siNETs) frequently present emergently due to bowel ischemia or bowel obstruction. The influence of emergency surgery on the prognosis of siNET remains controversial…
View article: 1147MO Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): An AIO phase II multicenter single-arm study
1147MO Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): An AIO phase II multicenter single-arm study Open
View article: Influence of Lymphatic, Microvascular and Perineural Invasion on Oncological Outcome in Patients with Neuroendocrine Tumors of the Small Intestine
Influence of Lymphatic, Microvascular and Perineural Invasion on Oncological Outcome in Patients with Neuroendocrine Tumors of the Small Intestine Open
For the histopathological work-up of resected neuroendocrine tumors of the small intestine (siNET), the determination of lymphatic (LI), microvascular (VI) and perineural (PnI) invasion is recommended. Their association with poorer prognos…
View article: Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy
Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy Open
Background: Pretherapeutic chromogranin A, alkaline phosphatase (ALP), or De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) are prognostic factors in patients with metastatic neuroendocrine tumors (NET) undergoing peptid…
View article: The Role of Alternative Lymph Node Classification Systems in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN): Superiority of a LODDS Scheme Over N Category in Pancreatic NEN (pNEN)
The Role of Alternative Lymph Node Classification Systems in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN): Superiority of a LODDS Scheme Over N Category in Pancreatic NEN (pNEN) Open
Lymph node (LN) involvement in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) has been reported to have prognostic and therapeutic implications. Numerous novel LN classifications exist; however, no comparison of their prognostic…
View article: Prognostic differences in grading and metastatic lymph node pattern in patients with small bowel neuroendocrine tumors
Prognostic differences in grading and metastatic lymph node pattern in patients with small bowel neuroendocrine tumors Open
View article: Osteopontin is a prognostic circulating biomarker in patients with neuroendocrine neoplasms
Osteopontin is a prognostic circulating biomarker in patients with neuroendocrine neoplasms Open
View article: Proposal of early <scp>CT</scp> morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to <scp>RECIST</scp>
Proposal of early <span>CT</span> morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to <span>RECIST</span> Open
RECIST 1.1 criteria are commonly used with computed tomography (CT) to evaluate the efficacy of systemic treatments in patients with neuroendocrine tumors (NETs) and liver metastases (LMs), but their relevance is questioned in this setting…
View article: Surgical Approach to Liver Metastases in GEP-NET in a Tertiary Reference Center
Surgical Approach to Liver Metastases in GEP-NET in a Tertiary Reference Center Open
Indications for liver resection in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) vary from liver resection with curative intent to tumor debulking or tissue sampling for histopathological characterization. With incre…
View article: Analyses of sex-based clinicopathological differences among patients with gastrointestinal neuroendocrine neoplasms in Europe
Analyses of sex-based clinicopathological differences among patients with gastrointestinal neuroendocrine neoplasms in Europe Open
Background Previous studies have found variations in cancer types, tumor progression, and disease outcomes between men and women. However, there is limited knowledge of the effect of sex on gastrointestinal neuroendocrine neoplasms (GI-NEN…
View article: Spectral Computed Tomography-Derived Iodine Content and Tumor Response in the Follow-Up of Neuroendocrine Tumors—A Single-Center Experience
Spectral Computed Tomography-Derived Iodine Content and Tumor Response in the Follow-Up of Neuroendocrine Tumors—A Single-Center Experience Open
Spectral computed tomography (SCT) allows iodine content (IC) calculation for characterization of hypervascularized neoplasms and thus might help in the staging of neuroendocrine tumors (NETs). This single-center prospective study analyzed…
View article: Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study Open
View article: Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy
Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy Open
Pancreatic neuroendocrine neoplasia constitute an important subentity of the gastroenteropancreatic neuroendocrine neoplasms accounting for up to 15% of all neuroendocrine neoplasm. Prognosis and oncological behavior of pancreatic neuroend…
View article: Inflammatory Cytokines Associated with Diagnosis, Tumor Grade and Prognosis in Patients with Neuroendocrine Tumors
Inflammatory Cytokines Associated with Diagnosis, Tumor Grade and Prognosis in Patients with Neuroendocrine Tumors Open
Background and aims: Inflammatory cytokines represent diagnostic and prognostic biomarkers in manifold cancers. Recent data suggest a pivotal role of these cytokines in different biological processes involved in the development of neuroend…
View article: Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice
Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice Open
Background: Neuroendocrine neoplasia grade 3 (NEN G3) represents a rare and heterogeneous cancer type with a poor prognosis. The aim of our study was to analyze real-world data from the German NET Registry with a focus on therapeutic and p…
View article: Distribution of gastrointestinal neuroendocrine tumors in Europe: results from a retrospective cross-sectional study
Distribution of gastrointestinal neuroendocrine tumors in Europe: results from a retrospective cross-sectional study Open
Background Gastrointestinal (non-pancreatic) neuroendocrine tumors (GI-NETs) represent a rare but increasingly common tumor entity. Prognosis and biological behavior of these tumors is extremely heterogenous and largely dependent on the sp…
View article: Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [177Lu]Lu-DOTATOC
Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [177Lu]Lu-DOTATOC Open
(1) Background: retreatment with radionuclide-labeled somatostatin analogues following disease progression after initial treatment cycles is often referred to as salvage peptide receptor radionuclide therapy (salvage PRRT). Salvage PRRT is…
View article: Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial
Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial Open
View article: 29 Elevated Flt3L predicts long-term survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
29 Elevated Flt3L predicts long-term survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms Open
Background Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are a rare and heterogeneous family of tumors arising from the disseminated neuroendocrine system of the gastrointestinal tract and pancreas. Clinical management of high-…
View article: Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms
Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms Open
Background: The clinical management of high-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) is challenging due to disease heterogeneity, illustrating the need for reliable biomarkers facilitating patient stratification and …